TEST:

Tempus TO

Lastly, given the significance of genomic biomarkers in the evolution of EEC FIGO staging, we stratified outcomes by the established TCGA subtypes as a reference standard and performed a subgroup analysis in patients classified as having no specific molecular profile (NSMP). Among patients who were NSMP, the MR-high group showed a significantly higher rate of distant recurrence in comparison to the MR-low group (HR=7.92, N=67).These evaluation studies demonstrate the performance of the GEP MR test in early-stage EEC distant recurrence risk stratification, specifically HIR patients, necessitating further studies to validate the test for clinical use in informing adjuvant clinical management.

Bansal from Saint Luke’s Health System and Dr. Chao from Tempus to learn how Tempus’ Pixel solutions use aggregated multimodal data to: Automate reporting from radiology images Help providers accurately track, quantify, and efficiently make RECIST assessments and other clinical decisions Screen, detect, and track changes in lesions suspected of breast cancer Detect and track longitudinal changes in lung nodules Analyze and quantify cardiac MR images Integrate insights into streamlined workflow management tools for tumor boards

Using real-world claims data, we show that molecular diagnostic testing utilizing Tempus TO impacted care for a majority of CUP patients. This cohort will be followed to identify how TO testing decisions impact outcomes. >

Combining diagnostic prediction tests (e.g., Tempus TO) with sequencing-based variant reporting (e.g., Tempus xT) may expand therapeutic options for patients with cancers of unknown primary or uncertain histology.

A case study that explores the use of comprehensive Tempus sequencing for oncology patients in the CVS transform oncology program. The session will explore the motivating factors for both CVS Health and Tempus to enter into the partnership and how they stayed focused on shared incentives as the program moved forward.

"Tempus...announced three abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which convenes in Paris, France from September 9-13, 2022. Tempus is presenting all three abstracts, including one oral presentation and two poster presentations."

When treatments changed, the drugs that were most often removed as treatments were: 5-FU (n=46), oxaliplatin (n=42), and carboplatin (n=41). Gemcitabine and cisplatin were added as treatment recommendations in 54 and 49 cases, respectively...Conclusions In our study, we demonstrate that the TO test can specify a diagnosis that alters the therapeutic management for up to 81% of patients with unknown primary. These changes include the addition and removal of chemotherapy and CPI, as well as alterations in radiation and surgical treatments, highlighting the potential of molecular classifiers to provide clinical insight into the management of CUP patients.